Printer Friendly

Shockwave Lithoplasty System for Peripheral Artery Disease Earns CE Mark.

M2 PHARMA-January 7, 2015-Shockwave Lithoplasty System for Peripheral Artery Disease Earns CE Mark

(C)2015 M2 COMMUNICATIONS

US-based vascular disease specialist Shockwave Medical Lithoplasty balloon catheters for the treatment of peripheral artery disease has earned CE Mark regulatory approval its, the company said on Wednesday.

Lithoplasty is a novel balloon-based technology that utilises integrated lithotripsy, a pulsatile mechanical energy commonly used to break up kidney stones, to disrupt both superficial and deep calcium and normalize vessel wall compliance prior to low-pressure balloon dilatation.

In advanced vascular disease, atherosclerosis becomes calcified deep inside the vessel walls, obstructing blood flow.

These deposits make current interventions challenging and prone to both procedural and long-term failure.Lithoplasty is designed to be naturally gentle on the soft, healthy, portions of the vessel, while remaining hard on difficult-to-treat calcified tissue.

Shockwave said its technology allows for low-pressure balloon dilatation, reducing the potential for soft tissue vascular injury, which is known to occur with current endovascular technologies.

CE Mark for Lithoplasty was supported by safety and utility clinical data from the multicenter Disrupt Pad study, which was presented in November 2014 at the Vascular Interventional Advances Annual Conference in Las Vegas, Nevada.

Early results demonstrated safe and effective dilatation of calcified stenosis with no acute failures, very favorable residual stenosis, no major adverse events and no restenosis out to 30 days.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jan 7, 2015
Words:235
Previous Article:NeuroMetrix Launches Wearable Pain Relief Technology.
Next Article:Gamida Cell receives orphan drug designation for NiCord from US Department of Health and Human Services.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters